ACAD10: A Promising Drug Target and Biomarker for the Acyl-CoA Dehydrogenase Family

Target Name: ACAD10

NCBI ID: G80724

ACAD10

ACAD10: A Promising Drug Target and Biomarker for the Acyl-CoA Dehydrogenase Family

The Acyl-CoA (acyl-CoA) dehydrogenase family member 10 (ACAD10) is a key enzyme involved in the metabolism of fatty acids and has been identified as a potential drug target and biomarker. This family of enzymes plays a crucial role in the production of fatty acids from the precursors, such as acyl-CoA, which are derived from dietary sources. The majority of the ACAD10 enzymes are cytoplasmic, which means they are located in the cytoplasm of the cell, while the remaining subfamily is located in the mitochondria.

Dietary Fatty Acids and ACAD10

Fatty acids are essential for various cellular processes, including energy production, membrane structure, and signaling pathways. The production of fatty acids from acyl-CoA is a critical step in the lipid metabolism pathway. The ACAD10 enzyme is involved in the production of fatty acids from acyl-CoA, which is a key precursor for the synthesis of fatty acids.

ACAD10 and Disease

Several diseases have been associated with mutations in the ACAD10 gene. These mutations have led to the production of abnormal acyl-CoA dehydrogenase enzymes, which have been linked to the development of various diseases, including obesity, diabetes, and fatty liver diseases. For example, mutations in the ACAD10 gene have been linked to the development of non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.

Drug Targeting ACAD10

The ACAD10 enzyme has been identified as a potential drug target due to its involvement in the production of fatty acids. Drugs that can inhibit the activity of ACAD10 have been shown to be effective in treating various diseases associated with the ACAD10 gene. For example, studies have shown that inhibitors of ACAD10 have been effective in reducing the amount of fat in the liver, which can be used to treat NASH.

Biomarker Development

ACAD10 has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases associated with the ACAD10 gene. The production of fatty acids from acyl-CoA is a critical step in the lipid metabolism pathway, and changes in the levels of fatty acids can be used as a biomarker for various diseases. For example, the levels of acyl-CoA in the blood can be used as a biomarker for the diagnosis of obesity.

Conclusion

In conclusion, ACAD10 is a key enzyme involved in the production of fatty acids from the precursors, such as acyl-CoA. The majority of the ACAD10 enzymes are cytoplasmic, which means they are located in the cytoplasm of the cell, while the remaining subfamily is located in the mitochondria. The production of fatty acids from acyl-CoA is a critical step in the lipid metabolism pathway and is associated with the development of various diseases. The inhibition of ACAD10 has been shown to be effective in treating various diseases associated with the ACAD10 gene, and ACAD10 has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases. Further research is needed to fully understand the role of ACAD10 in the production of fatty acids and its potential as a drug target and biomarker.

Protein Name: Acyl-CoA Dehydrogenase Family Member 10

Functions: Acyl-CoA dehydrogenase only active with R- and S-2-methyl-C15-CoA

The "ACAD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACAD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets